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Background. Pregnant and breastfeeding women are at risk for folate deficiency. Folate supplementation has been shown to be
associated with enhanced markers of folate status. However, dose-response analyses for adult women are still lacking. Objective.
To assess the dose-response relationship between total folate intake (folic acid plus dietary folate) and markers of folate status
(plasma/serum folate, red blood cell folate, and plasma homocysteine); to evaluate potential diﬀerences between women in
childbearing age, pregnant and lactating women. Methods. Electronic literature searches were carried out on three databases until
February 2010. The overall pooled regression coeﬃcient (β) and SE(β) were calculated using meta-analysis on a double-log scale.
Results. The majority of data was based on nonpregnant, nonlactating women in childbearingage. The pooled estimate of the
relationship between folate intake and serum/plasma folate was 0.56 (95% CI = 0.40–0.72, P < 0.00001); that is, the doubling of
folate intake increases the folate level in serum/plasma by 47%. For red blood cell folate, the pooled-eﬀect estimate was 0.30 (95%
CI = 0.22–0.38, P < 0.00001), that is, +23% for doubling intake. For plasma-homocysteine it was –0.10 (95% = –0.17 to –0.04,
P = 0.001), that is, –7% for doubling the intake. Associations tended to be weaker in pregnant and lactating women. Conclusion.
Significant relationships between folate intake and serum/plasma folate, red blood cell folate, and plasma homocysteine were
quantified. This dose-response methodology may be applied for setting requirements for women in childbearing age, as well as for
pregnant and lactating women.
1. Introduction
Folate is involved in one-carbon transfer reactions, which
are fundamental for DNA and RNA synthesis, amino acid
metabolism, and formate oxidation [1]. Plasma or serum
folate, red blood cell (RBC) folate, and homocysteine
(tHcy) are used as biomarkers of folate status and reflect
reliably changes in folate intakes [2, 3]. Serum folate reflects
primarily recent intake, whereas erythrocyte folate levels
reflect time-integrated intake and are considered to be a
measure of long-term folate status [4]. Plasma homocysteine
is an indicator of low or deficient folate status, and therefore
considered as an indicator of folate adequacy [5] on the basis
that normal homocysteine metabolism requires an adequate
supply of folate [6].
Folate intake and status play a crucial role during
pregnancy [7]. Pregnant and breastfeeding women are at
risk for folate deficiency due to an increased need for
folate. Previously, a longitudinal study showed low folate
status among participants, especially in late pregnancy and
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during lactation [3]. Moreover, a meta-analysis including
twenty-one controlled trials on folate supplementation in
pregnant women showed that compared to placebo or
no supplementation, folate supplementation was associated
with strongly increased serum folate levels and red cell
folate levels [8]. Regarding breastfeeding, a review of the
literature indicates that apparently healthy women, who do
not receive folic acid supplementation, can already become
folate depleted in the early postpartum [9].
Deriving a dose-response associationmay help to address
the above issues and identify major modifiers of the intake-
status relationship, useful to address questions on the
“optimal” level of a folate biomarker and to recommend-
ing intake of folic acid/folate for mother’s and newborn’s
health. Actually, the adequate folate intake during pregnancy
has not been clearly stated yet. Six hundred μg/day DFEs
(Dietary Folate Equivalents) are considered suﬃcient to
maintain adequate folate status in pregnant women [10–
12]. Nordic Nutrition Recommendations [13] recommend
500 μg/day DFE while the dietary reference intakes of total
folate are 400 μg/day in Italy [14] and 300 μg/day in UK
[15]. Internationally, women are advised to use folic acid
supplements during the periconceptional period on the basis
of the well-recognized link between maternal folate status
and neural tube defects (NTDs) [16]. Some debate also
exists regarding the proper daily dosage of folic acid/folate
for preventing NTDs [17]. The current recommendation to
supplement 400 μg folic acid daily starting at least 4 weeks
before conception which seems to be not enough to achieve
optimal-red-cell-folate levels within 4 weeks, because this
requires at least 8–12 weeks of daily intake [18]. In contrast,
with 800 μg folic acid, the health criterion is reached within
an average of 4 weeks after the start of supplementation
[19]. Regarding lactating women, for example, Mackey and
Picciano [20] found that folate status in lactating women
was preserved with 1mg/day of supplemental folate for three
months.
However, the strength of the dose-response relationship
between folate intake and folate biomarkers has not been
established yet, except for the relation with risk of NTDs in
women aged 20–65 years [21]. Consequently, we used meta-
analysis to model folate status as a function of supplemental
folate intake. We conducted a meta-analysis of data from
randomised controlled studies (RCTs) that examined the
eﬀect of folate exposure on folate status in women in
childbearing age, pregnant and lactating women, in order to
quantitatively assess folate dose-response relationships.
2. Methods
This research is part of a project within the European
Micronutrient Recommendations Aligned (EURRECA) Net-
work of Excellence that aims to identify micronutrient
requirements for optimal health in European populations
[22]. The review here reported was part of a wider review
process to identify studies assessing the eﬀect of folate intake
on both diﬀerent markers of folate status as well as health
outcomes.
3. Electronic Searches
The methodology here used is based on a standard method-
ology developed for EURRECA reviews [23]. A protocol was
provided outlining specific linkages among the populations
of interest, exposures, modifying factors, biological role of
folate, and outcomes of interest, in order to define study
eligibility criteria prior to starting the literature search and
in order to interpret relevant studies once they are identified.
The general search strategy included terms for randomised
controlled trials in humans AND (intake or status) AND
(folate or folic acid or vitamin B9). Electronic searches
were carried out over all years until February 2010. Both
indexing and text terms were used and each search strategy
was further adapted for the individual databases searched
(Ovid EMBASE, Ovid Medline, and Cochrane Central). The
reference lists of collected articles and of published reviews
were also checked for relevant studies to be included into the
screening and data extraction process.
4. Data Collection
The results of the searches were combined, and papers were
screened on the basis of title and abstract; references clearly
not meeting the review criteria were excluded. This task was
divided between two independent reviewers (K. Fekete and
C. Berti), with a minimum of 10% overlapping in order to
harmonise the process. Once potentially relevant literature
was identified, full-text articles were retrieved and reviewed
for inclusion on the basis of the predetermined inclu-
sion/exclusion criteria (Table 1). Only papers meeting all
criteria were included and extracted onto an Access database
by a single reviewer (C. Berti). Corresponding authors of
papers were contacted to obtain values or data when data
in the original articles were not clear or presented as graph.
Information pertaining to bibliographic details, and study
characteristics, as well as nutrient supplement information
such as intake/dose, source of micronutrient, chemical form,
mode of delivery, duration of delivery, chemical analysis,
measures of prior nutritional status, level of the nutrient
in the background diet, method used to estimate intake,
and analytical methods used to assess nutrient status were
collated.
5. Assessment of Internal Validity
In order to assess the risk of bias of the studies, the
following indicators of internal validity specific to the RCT
methodology were collected during data extraction: (1)
method of sequence generation and allocation, (2) blinding,
(3) potential funding bias, (4) number of participants at
start, (5) dropouts and dropout reasons, (6) dose check,
(7) dietary intake data reported, (8) outcome comparability
and reproducibility, and (9) similarity of most and least
exposed groups at baseline. Based on these indicators, two
reviewers decided on the overall risk of bias. Disagreements
were resolved by discussion. The criteria for judging these
indicators were adapted from the Cochrane Handbook [38].
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Table 1: Inclusion criteria followed to select potentially relevant
papers for data extraction.
Population
characteristics
Apparently healthy participants at baseline
Study design Randomised controlled trial
Intervention
Supplements or fortified foods or natural
diet intakes versus a placebo or untreated
group
Duration 4 weeks
Outcomes
Must report the following relationships:
intake-status
Intake measures
Report of intake from supplements or
fortified foods or natural food sources
Status
measurements
Red blood cell (RBC) folate
Plasma/serum folate
Homocysteine (tHcy)
Baseline
information
Baseline data must be present for all
reported outcomes
6. Data Analysis
The eﬀect of total folate intake (folic acid plus dietary folate),
expressed as μg/d DFEs [39], was investigated through meta-
analysis of the intervention group compared with the control
group for all included studies that assessed the specified
biomarkers of folate status. Based on the assumption that the
bioavailability of folic acid added to food is greater than that
of natural food folate by a factor of 1.7, the amounts of folic
acid from supplements/fortified foods were transformed into
amounts of folate by multiplying × 1.7 [6, 39]. In the studies
evaluating the eﬀects of supplements or fortified foods, when
dietary intake was not provided, the mean dietary folate
intake of 247 μg/day from other comparable studies was used
in the calculation. If required, concentration data expressed
as nmol/l were converted to the SI units conventional μg/L
(i.e., ng/mL) by dividing by the conversion factor (i.e., 2.266).
We calculated an intake-status regression coeﬃcient
(̂β) and the corresponding standard error (SE) for each
individual study [40]. The intake-status relationship was
assumed to be linear on the ln-ln-scale (natural logarithm of
intake versus natural logarithm of status). This assumption
is based upon our hypothesis that within the range of
observations, the true intake-status relationship for folate
can be described by amonotonic concave curve, which slowly
grows to positive infinity as intake increases and rapidly goes
to negative infinity as intake approaches 0. We calculated
the overall pooled β and its SE using random eﬀects
meta-analysis, which estimates the between-study variance
using the method of DerSimonian and Laird [41] and uses
this estimate to modify the weights used to calculate the
summary estimate. Residual heterogeneity between studies
was evaluated using the I2 statistic. A priori defined subgroup
analyses according to dose, duration of supplementation,
and population group were carried out to try to explain
the heterogeneity. Meta-analysis was carried out with Review
Manager (RevMan) 5.0 (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2008).
7. Results
Figure 1 shows the flow diagram outlining the search results
for pregnant and lactating women. Of the overall 4067 hits
recovered through the general search, after the removal of
duplicates and titles and abstracts highly unlikely to be
relevant for the aims of this paper (data not shown), a total
of 283 titles and abstracts were potentially available. After
inclusion of studies from bibliographic searches, title and
abstract were screened, 136 were collected as full-text articles,
and 15 articles fulfilled the inclusion criteria. Papers were
excluded because they were review articles, or dealt with not
interventional studies, or with trial inappropriately designed
or with intervention studies including other population
groups or nonhealthy women or without the minimal
duration or dealt with combined intervention where the
eﬀects could not be attributed solely to folic acid. Also, papers
with incomplete data not obtainable from the authors were
excluded.
Characteristics of the included studies are summarised
in Table 2. Eight studies compared the placebo group with
more than one intervention group [18, 24–31, 36]. The
majority of interventions assessed the eﬀect of folic acid
from supplements (n = 14), while only one used fortified
foods [32]. Four studies [18, 30, 31, 36] were designed as
three-arm trials, comparing placebo to both folic acid and 5-
methyltetrahydrofolate or [6S]-5-methyltetrahydrofolate (5-
MTHF) or racemic MTHF. We analysed the two types of
supplement separately.
Ten studies included women in childbearing age, three
were on pregnant women [33–35] and two included lactating
women [20, 36]. Placebo was used in the control group in the
majority of studies except for two studies [27, 33] in which
the control group did not undergo any treatment. Only one
study included pregnant adolescents [35]. Most of the trials
(i.e., ten) were conducted in Europe, two inNew Zealand [24,
32], one was in Brazil [35], one in Canada [36], and one in
the USA [20].
The majority of the studies (e.g., 12 out of 15) presented
a moderate risk of bias (data not shown). The most common
reason for this was an overall lack of information about
the method of randomization (i.e., inadequate or unclear
sequence generation and/or allocation) and/or unclear
source of funding. In contrast, most of the trials reported
reasons for dropouts and numbers of dropouts, as well as
information on compliance (i.e., methods, number of no
compliants or dose check).
8. Serum/Plasma Folate
We identified nine studies that reported the eﬀect of specified
doses of folic acid up to 1.0mg/day plus dietary folate
on serum/plasma folate. Three trials were in pregnant
women, four in women in childbearing age, and two studies
during the postpartum period. Overall, 632 participants were
included in the studies with a duration ranging from 4 to 25
weeks. For further details on the characteristics of included
studies, see Table 2.
4 Journal of Nutrition and Metabolism
T
a
bl
e
2:
G
en
er
al
ch
ar
ac
te
ri
st
ic
s
of
th
e
in
cl
u
de
d
st
u
di
es
an
d
eﬀ
ec
ts
on
th
e
bi
om
ar
ke
rs
of
fo
la
te
in
te
rv
en
ti
on
in
w
om
en
of
ch
ild
be
ar
in
g
ag
e,
pr
eg
n
an
t
an
d
la
ct
at
in
g
w
om
en
,w
it
h
re
sp
ec
t
to
th
e
co
n
tr
ol
/p
la
ce
bo
ac
co
rd
in
g
to
th
e
or
ig
in
al
pa
pe
r.
A
u
th
or
,y
ea
r
C
ou
n
tr
y
Po
pu
la
ti
on
(n
.
in
cl
u
de
d)
D
es
cr
ip
ti
on
of
su
pp
ly
N
.i
n
in
te
rv
en
ti
on
(F
A
)
an
d
in
co
n
tr
ol
gr
ou
ps
(P
)
at
la
te
st
ti
m
e
St
u
dy
de
si
gn
B
io
m
ar
ke
rs
re
po
rt
ed
P
va
lu
e
A
da
n
k
et
al
.,
20
03
[2
4]
N
ew
Z
ea
la
n
d
C
h
ild
be
ar
in
g
ag
e
w
om
en
(2
39
)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
Fo
lic
ac
id
ca
ps
u
le
=
28
00
μ
g/
w
ee
k.
P
la
ce
bo
ca
ps
u
le
FA
(4
00
)
=
36
P
=
44
D
ou
bl
e
bl
in
d.
D
u
ra
ti
on
:1
2
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
fo
la
te
(n
m
ol
/L
)
(M
ic
ro
ti
te
r
te
ch
n
iq
u
e,
L
.
C
as
ei
).
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(fl
u
or
es
ce
n
ce
po
la
ri
za
ti
on
im
m
u
n
oa
ss
ay
).
<
0.
00
1
<
0.
05
B
ro
uw
er
et
al
.,
19
99
1
[2
5]
N
et
h
er
la
n
ds
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
44
)
Fo
lic
ac
id
ta
bl
et
=
25
0
μ
g/
da
y
(5
00
μ
g
fo
lic
ac
id
an
d
a
pl
ac
eb
o
ta
bl
et
ev
er
y
se
co
n
d
da
y)
.
Fo
lic
ac
id
ta
bl
et
=
50
0
μ
g/
da
y.
P
la
ce
bo
ta
bl
et
.
FA
(2
50
)
=
50
FA
(5
00
)
=
45
P
=
49
D
ou
bl
e
bl
in
d,
2
co
n
ta
in
er
s
of
in
di
st
in
gu
is
h
ab
le
ta
bl
et
s:
on
e
re
d
m
ar
ke
d,
on
e
ye
llo
w
m
ar
ke
d.
D
u
ra
ti
on
:4
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
fo
la
te
(n
m
ol
/L
)
(I
m
x
au
to
m
at
ed
im
m
u
n
oa
ss
ay
sy
st
em
).
P
la
sm
a
fo
la
te
(I
m
x
au
to
m
at
ed
im
m
u
n
oa
ss
ay
sy
st
em
).
FA
(2
50
):
a
<
0.
01
FA
(5
00
):
a
<
0.
00
1
FA
(2
50
):
a
<
0.
00
1
FA
(5
00
):
a
<
0.
00
1
B
ro
uw
er
et
al
.,
19
99
2
[2
6]
N
et
h
er
la
n
ds
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
44
)
Fo
lic
ac
id
ta
bl
et
=
25
0
μ
g/
da
y
(5
00
μ
g
fo
lic
ac
id
ev
er
y
th
e
2n
d
da
y)
.
Fo
lic
ac
id
ta
bl
et
=
50
0
μ
g/
da
y.
P
la
ce
bo
ta
bl
et
.
FA
(2
50
)
=
50
FA
(5
00
)
=
45
P
=
49
D
ou
bl
e
bl
in
d,
2
co
n
ta
in
er
s
of
in
di
st
in
gu
is
h
ab
le
ta
bl
et
s:
on
e
re
d-
m
ar
ke
d,
on
e
ye
llo
w
-m
ar
ke
d.
D
u
ra
ti
on
:4
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(H
P
LC
an
d
fl
u
or
im
et
ri
c
de
te
ct
io
n
)
FA
(2
50
):
a
<
0.
01
FA
(5
00
):
a
<
0.
00
1
C
u
sk
el
ly
et
al
.,
19
96
[2
7]
U
K
C
h
ild
be
ar
in
g
ag
e
w
om
en
(4
9)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
Fo
lic
-a
ci
d-
fo
rt
ifi
ed
fo
od
s
pl
u
s
40
0
μ
g/
da
y
(F
A
-f
).
D
ie
ta
ry
fo
la
te
pl
u
s
40
0
μ
g/
da
y
(F
A
-d
).
D
ie
ta
ry
ad
vi
ce
(D
A
)
C
on
tr
ol
gr
ou
p:
n
o
tr
ea
tm
en
t
FA
=
9
FA
-f
=
6
FA
-d
=
10
D
A
=
7
P
=
9
D
u
ra
ti
on
:1
2
w
ks
m
os
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
fo
la
te
(μ
g/
L
)
(m
ic
ro
bi
ol
og
ic
al
as
sa
y)
D
al
y
et
al
.,
19
97
[2
8]
Ir
el
an
d
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
10
)
Fo
lic
ac
id
ta
bl
et
=
20
0–
40
0
μ
g/
da
y.
P
la
ce
bo
ta
bl
et
FA
(1
00
)
=
22
FA
(2
00
)
=
28
FA
(4
00
)
=
26
P
=
19
D
ou
bl
e
bl
in
d,
id
en
ti
ca
l
ta
bl
et
s.
D
u
ra
ti
on
:2
4
w
ks
R
B
C
fo
la
te
(μ
g/
L
)
(m
ic
ro
bi
ol
og
ic
al
as
sa
y)
D
al
y
et
al
.,
20
02
[2
9]
Ir
el
an
d
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
10
)
Fo
lic
ac
id
ta
bl
et
=
20
0–
40
0
μ
g/
da
y.
P
la
ce
bo
ta
bl
et
FA
(1
00
)
=
21
FA
(2
00
)
=
28
FA
(4
00
)
=
26
P
=
19
D
ou
bl
e
bl
in
d,
id
en
ti
ca
l
ta
bl
et
s.
D
u
ra
ti
on
:1
0
w
ks
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(a
u
to
m
at
ed
fl
u
or
es
ce
n
ce
-p
ol
ar
iz
at
io
n
m
et
h
od
).
La
m
er
s
et
al
.,
20
04
[3
0]
G
er
m
an
y
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
44
)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
[6
S]
-5
-M
T
H
F
ca
ps
u
le
=
41
6
μ
g/
da
y.
[6
S]
-5
-M
T
H
F
ca
ps
u
le
=
20
8
μ
g/
da
y.
P
la
ce
bo
ca
ps
u
le
FA
=
34
Lo
w
M
T
H
F
=
32
H
ig
h
M
T
H
F
=
35
P
=
34
D
ou
bl
e
bl
in
d,
h
ar
d
ge
la
ti
n
e
ca
ps
u
le
s
D
u
ra
ti
on
:2
4
w
ks
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(i
m
m
u
n
oa
ss
ay
on
A
xS
Y
M
an
al
ys
er
).
FA
:a
<
0.
01
Lo
w
M
T
H
F:
a
<
0.
01
H
ig
h
M
T
H
F:
a
<
0.
01
Journal of Nutrition and Metabolism 5
T
a
bl
e
2:
C
on
ti
n
u
ed
.
A
u
th
or
,y
ea
r
C
ou
n
tr
y
Po
pu
la
ti
on
(n
.
in
cl
u
de
d)
D
es
cr
ip
ti
on
of
su
pp
ly
N
.i
n
in
te
rv
en
ti
on
(F
A
)
an
d
in
co
n
tr
ol
gr
ou
ps
(P
)
at
la
te
st
ti
m
e
St
u
dy
de
si
gn
B
io
m
ar
ke
rs
re
po
rt
ed
P
va
lu
e
La
m
er
s
et
al
.,
20
06
∗
[1
8]
G
er
m
an
y
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
44
)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
[6
S]
-5
-M
T
H
F
ca
ps
u
le
=
41
6
μ
g/
da
y.
[6
S]
-5
-M
T
H
F
ca
ps
u
le
=
20
8
μ
g/
da
y.
P
la
ce
bo
ca
ps
u
le
FA
=
34
Lo
w
M
T
H
F
=
33
H
ig
h
M
T
H
F
=
35
P
=
34
D
ou
bl
e
bl
in
d,
h
ar
d
ge
la
ti
n
e
ca
ps
u
le
s.
D
u
ra
ti
on
:2
4
w
ks
.
R
ed
bl
oo
d
ce
ll
fo
la
te
(n
m
ol
/L
)
({
(w
h
ol
e
bl
oo
d
fo
la
te
×
10
0)
–
(p
la
sm
a
fo
la
te
×
(1
00
–
h
em
at
oc
ri
t)
)}
).
P
la
sm
a
fo
la
te
(n
m
ol
/L
)
(m
ic
ro
bi
ol
og
ic
al
as
sa
y)
Fo
h
r
et
al
.,
20
02
[3
1]
G
er
m
an
y
C
h
ild
be
ar
in
g
ag
e
w
om
en
(1
63
)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
M
T
H
F
(r
ac
em
ic
m
ix
tu
re
)
ca
ps
u
le
=
48
0
μ
g/
da
y.
P
la
ce
bo
ca
ps
u
le
FA
=
51
M
T
H
F
=
52
P
=
57
D
ou
bl
e
bl
in
d.
D
u
ra
ti
on
:8
w
ks
.
R
B
C
fo
la
te
(n
m
ol
/L
)
(i
m
m
u
n
oa
ss
ay
ki
t
fo
r
IM
x
an
al
ys
er
).
P
la
sm
a
fo
la
te
(n
m
ol
/L
)
(i
m
m
u
n
oa
ss
ay
ki
t
fo
r
IM
x
an
al
ys
er
).
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(r
ev
er
se
d-
ph
as
e
H
P
LC
).
G
re
en
et
al
.,
20
05
[3
2]
N
ew
Z
ea
la
n
d
C
h
ild
be
ar
in
g
ag
e
w
om
en
(7
3)
75
g
po
w
de
re
d
m
ilk
da
ily
.
Fo
rt
ifi
ed
m
ilk
=
37
5
μ
g
fo
lic
ac
id
/d
ay
.
C
on
tr
ol
m
ilk
FA
=
36
P
=
37
D
ou
bl
e
bl
in
d.
D
u
ra
ti
on
:1
2
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
fo
la
te
(n
m
ol
/L
)
(f
ro
m
w
h
ol
e
bl
oo
d
fo
la
te
by
su
bt
ra
ct
in
g
pl
as
m
a
fo
la
te
an
d
co
rr
ec
ti
n
g
fo
r
h
em
at
oc
ri
t)
.
P
la
sm
a
fo
la
te
(n
m
ol
/L
)
(m
ic
ro
ti
te
r
te
ch
n
iq
u
e,
ch
lo
ra
m
ph
en
ic
ol
re
si
st
an
t,
L.
C
as
ei
).
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(I
m
x
an
al
yz
er
).
E
lli
so
n
et
al
.,
20
04
[3
3]
U
K
P
re
gn
an
t
w
om
en
(3
0)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
C
on
tr
ol
gr
ou
p:
n
o
tr
ea
tm
en
t.
FA
=
15
P
=
15
D
u
ra
ti
on
:2
4
w
ks
.
P
la
m
a
fo
la
te
(n
g/
m
L
).
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(e
n
zy
m
e
im
m
u
n
oa
ss
ay
).
<
0.
05
Li
ra
et
al
.,
19
89
[3
4]
Sp
ai
n
P
re
gn
an
t
w
om
en
(1
53
)
M
u
lt
iv
it
am
in
ca
ps
u
le
s.
Su
pp
le
m
en
t
=
35
0
μ
g
fo
lic
ac
id
,1
05
m
g
fe
rr
ou
s
su
lp
h
at
e,
50
0
m
g
as
co
rb
ic
ac
id
,
da
ily
.
P
la
ce
bo
=
10
5
m
g
fe
rr
ou
s
su
lp
h
at
e,
50
0
m
g
as
co
rb
ic
ac
id
,d
ai
ly
.
FA
=
75
P
=
78
R
an
ge
:0
–3
50
μ
g/
da
y.
D
u
ra
ti
on
:2
5
w
ks
.
R
B
C
fo
la
te
(μ
g/
L)
(L
.C
as
ei
m
ic
ro
bi
ol
og
ic
al
as
sa
y)
.
Se
ru
m
fo
la
te
(μ
g/
L
)
(L
.
C
as
ei
m
ic
ro
bi
ol
og
ic
al
as
sa
y)
.
<
0.
00
1
<
0.
00
1
N
og
u
ei
ra
et
al
.,
20
03
[3
5]
B
ra
zi
l
P
re
gn
an
t
w
om
en
(1
14
)
M
in
er
al
ta
bl
et
s.
Su
pp
le
m
en
t
=
25
0
μ
g
fo
lic
ac
id
,1
20
m
g
ir
on
su
lp
h
at
e/
da
y.
P
la
ce
bo
:1
20
ir
on
su
lp
h
at
e/
da
y.
FA
=
15
P
=
16
D
u
ra
ti
on
:2
2
w
ks
.
P
la
sm
a
fo
la
te
(m
g/
m
L)
(R
ad
io
im
m
u
n
oa
ss
ay
-
Io
do
12
5)
.
6 Journal of Nutrition and Metabolism
T
a
bl
e
2:
C
on
ti
n
u
ed
.
A
u
th
or
,y
ea
r
C
ou
n
tr
y
Po
pu
la
ti
on
(n
.
in
cl
u
de
d)
D
es
cr
ip
ti
on
of
su
pp
ly
N
.i
n
in
te
rv
en
ti
on
(F
A
)
an
d
in
co
n
tr
ol
gr
ou
ps
(P
)
at
la
te
st
ti
m
e
St
u
dy
de
si
gn
B
io
m
ar
ke
rs
re
po
rt
ed
P
va
lu
e
H
ou
gh
to
n
et
al
.,
20
06
[3
6]
C
an
ad
a
L
ac
ta
ti
n
g
w
om
en
(6
9)
Fo
lic
ac
id
ca
ps
u
le
=
40
0
μ
g/
da
y.
[6
S]
-5
-M
T
H
F
ca
ps
u
le
=
41
6
μ
g/
da
y.
P
la
ce
bo
ca
ps
u
le
FA
=
21
M
T
H
F
=
21
P
=
22
D
ou
bl
e
bl
in
d.
D
u
ra
ti
on
:1
6
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
(n
m
ol
/L
)
(f
ro
m
th
e
w
h
ol
e-
bl
oo
d
fo
la
te
by
su
bt
ra
ct
in
g
pl
as
m
a
fo
la
te
an
d
co
rr
ec
ti
n
g
fo
r
h
em
at
oc
ri
t)
.
P
la
sm
a
fo
la
te
(n
m
ol
/L
)
(L
.
rh
am
n
os
u
s
m
ic
ro
bi
ol
og
ic
al
as
sa
y)
.
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(H
P
LC
)
FA
:<
0.
00
2
M
T
H
F:
<
0.
00
01
M
T
H
F:
<
0.
00
2
M
ac
ke
y
an
d
P
ic
ci
an
o,
19
99
[2
0]
U
SA
L
ac
ta
ti
n
g
w
om
en
(4
2)
Fo
lic
ac
id
ca
ps
u
le
s
=
1
m
g/
da
y.
P
la
ce
bo
ta
bl
et
FA
=
21
P
=
21
D
ou
bl
e
bl
in
d,
fo
lic
ac
id
ta
bl
et
s
in
di
st
in
gu
is
h
ab
le
fr
om
pl
ac
eb
o
ta
bl
et
s.
D
u
ra
ti
on
:1
2
w
ks
.
D
ie
ta
ry
as
se
ss
m
en
t
R
B
C
fo
la
te
(n
m
ol
/L
)
(L
.
C
as
ei
m
ic
ro
bi
ol
og
ic
al
as
sa
y)
.
P
la
sm
a
fo
la
te
(n
m
ol
/L
)
(L
.
C
as
ei
m
ic
ro
bi
ol
og
ic
al
as
sa
y)
.
P
la
sm
a
h
om
oc
ys
te
in
e
(μ
m
ol
/L
)
(H
P
LC
).
<
0.
05
∗
T
h
e
A
u
th
or
s
ki
n
dl
y
re
qu
es
te
d
u
s
to
ci
te
bo
th
th
e
pu
bl
ic
at
io
n
in
A
JC
N
[1
8]
an
d
La
m
er
s’
P
h
.D
.t
h
es
is
fo
r
th
e
ra
w
da
ta
[3
7]
.
R
C
B
:r
ed
bl
oo
d
ce
ll.
a S
ig
n
ifi
ca
n
t
di
ﬀ
er
en
ce
s
be
tw
ee
n
th
e
ba
se
lin
e
an
d
th
e
en
d
of
th
e
tr
ea
tm
en
t.
FA
:f
ol
ic
ac
id
.
M
T
H
F:
m
et
hy
lt
et
ra
hy
dr
of
ol
at
e.
Journal of Nutrition and Metabolism 7
Titles and abstracts retrieved from
electronic, bibliographic, and expert
searches: 283
Titles and abstracts very
unlikely to be relevant: 147
Titles and abstracts appeared
potentially relevant, and collected
as full texts: 136
Full papers meeting inclusion
criteria: 15
•
•
•
Plasma folate: 9
Erythrocyte folate: 10
Plasma total homocysteine: 9
Excluded studies: 121
Not RCTs (n = 46), cluster RCTs (n = 7), not adequate control group
(n = 11): 64 
Inadequate results for the biomarkers of interest: 15
No values provided for the biomarkers of interest: 9
Combined interventions where the eﬀect could not be attributed to
folic acid/folate only: 16
Review (n = 5), only abstract (n = 3): 8
Other micronutrient or other population: 3
Not apparently healthy women: 6
Figure 1: Flow diagram of the articles screened, assessed, and excluded at various stages for this paper.
The forest plot of serum/plasma folate response to folic
acid plus dietary folate supply is shown in Table 4. The
overall pooled estimate was 0.56 (95% CI = 0.40–0.72), and
a significant eﬀect of folate on serum/plasma concentrations
was demonstrated (P < 0.00001). This means that a 2-
fold higher folate intake corresponds to a 1.47-fold higher
serum/plasma folate, that is, a 47% increase. The test for
heterogeneity showed high heterogeneity among the studies.
When subgroup analyses were carried out, heterogeneity
remained high within these subgroups (Table 3). The results
of the meta-analysis derive mainly from the trials on women
in childbearing age which represented half of all subjects.
When the eﬀect of 5-MTHF plus dietary folate was
quantified in three studies in a total of 221 women, we found
an overall pooled estimate (95% CI) of =1.18 (0.65, 1.71);
P < 0.0001 (Table 4). A doubling of 5-MTHF intake will lead
to increase serum/plasma folate levels by 2.26-fold, that is,
126%.
9. Red Blood Cell Folate
Ten trials contained eligible data regarding the eﬀects of folic
acid up to 1.0mg/day plus dietary folate on (RBC) folate.
These trials included 724 women. Supplements were taken
between 4 and 24 weeks. These trials primarily involved
women of childbearing age (seven trials), whereas only
one trial included pregnant women and two trials included
women during the post partum period. For further details
on the characteristics of included studies, see Table 2. As
demonstrated in Table 5, pooling response to folic acid/folate
supplementation in one meta-analysis yielded an overall
pooled Beta (95% CI) of 0.30 [0.22, 0.38]; P < 0.00001).
This means that doubling the intake of folic acid leads to an
23% increase of RBC folate concentrations. Primary analysis
was highly heterogeneous. Stratified analyses did not reduce
substantially the level of heterogeneity (Table 3). The results
of the meta-analysis are highly influenced by the trials with
women of childbearing age, because they represented the
majority of subjects (486 out of 724) included in the meta-
analysis.
Among the 10 studies, three also administered 5-MTHF
plus dietary folate in a total of 221 women. When combined
in meta-analysis, the overall pooled estimate was 0.49 (0.20,
0.77) (P = 0.0008) (Table 5).
10. Plasma tHcy
We identified nine studies that reported the eﬀect of specified
doses of folic acid up to 1.0mg/day plus dietary folate on
plasma tHcy. The intervention duration ranged from 4 to
24 weeks. These trials were mostly conducted in women
in childbearing age (six trials), one was conducting during
pregnancy, and two studies were in women during the
postpartum period. For further details on the characteristics
of included studies, see Table 2. The primary analysis of
the trials (Table 6) suggested that daily folic acid/folate was
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Table 4: Forest plot of the eﬀects of total folate supply (i.e., supplement plus dietary folate), with the supplement provided in form of folic
acid and [6S]-5-methyltetrahydrofolate [5-MTHF] on serum or plasma folate in childbearing age, pregnant and lactating women.
Study or subgroup Beta SE Weight Beta
IV, Random, 95% CI
Beta
IV, Random, 95% CI
Folic acid
−2 −1 0 1 2
Brouwer et al., 1999 1 [26] 0.35741049 0.04126697 12.5% 0.36 [0.28, 0.44]
Ellison et al., 2004 [33] 0.53050104 0.09332632 11.1% 0.53 [0.35, 0.71]
Fohr et al., 2002 a [31] 0.53023607 0.04406458 12.5% 0.53 [0.44, 0.62]
Green et al., 2005 [32] 1.00981877 0.06717076 11.9% 1.01 [0.88, 1.14]
Houghton et al., 2006 f [36] 0.57853113 0.09878823 10.9% 0.53 [0.38, 0.77]
Lamers et al., 2006 c [18] 0.7384753 0.06637089 11.9% 0.74 [0.61, 0.87]
Lira et al., 1989 [34] 0.37051554 0.06476415 12.0% 0.37 [0.24, 0.50]
Mackey and Picciano, 1999 [20] 0.13206921 0.10234828 10.8% 0.13 [−0.07, 0.33]
Nogueira et al., 2003 [35] 0.94291343 0.24037313 6.3% 0.94 [0.47, 1.41]
Subtotal (95% CI) 100.0% 0.56 [0.40, 0.72]
Heterogeneity: Tau2 = 0.05; Chi2 = 102.70, df = 8 (P < 0.00001); I2 = 92%
Test for overall eﬀect: Z = 6.68 (P < 0.00001)
5-MTHF
Fohr et al., 2002 b [31] 1.65921221 0.05130933 35.0% 1.66 [1.56, 1.76]
Houghton et al., 2006 g [36] 0.74857769 0.17130372 31.0% 0.75 [0.41, 1.03]
Lamers et al., 2006 e [18] 1.06897313 0.0904731 34.0% 1.07 [0.39, 1.25]
Subtotal (95% CI) 100.0% 1.18 [0.65, 1.71]
Heterogeneity: Tau2 = 0.21; Chi2 = 50.98, df = 2 (P < 0.00001); I2 = 96%
Test for overall eﬀect: Z = 4.35 (P < 0.0001)
∗
The Authors kindly requested us to cite both the publication in AJCN [18] and Lamers’ Ph.D. thesis for the raw data [37].
RCB: red blood cell.
aSignificant diﬀerences between the baseline and the end of the treatment.
FA: folic acid.
MTHF: methyltetrahydrofolate.
significantly inversely associated with tHcy concentrations
(overall pooled Beta; Beta-random eﬀect (95% CI) = −0.10
(−0.17, −0.04); P = 0.001, n = 585). Consequently, a
doubling of folate intake lowers the levels of tHcy by 7%.
The heterogeneity was high and therefore subgroup analysis
was conducted (Table 3). This showed that heterogeneity was
lower in the subgroup of trials in women in childbearing
age and breastfeeding, as well as in the subgroup of trials
with a duration of 4–12 weeks of supplementation. Again,
the majority of subjects in the meta-analysis were women of
childbearing age.
Of the studies, three also evaluated the eﬀect of 5-MTHF
plus dietary folate in a total of 221 women. An inverse, but
not statistically significant association, was found between
5-MTHF and plasma tHcy (overall pooled Beta [95% CI] =
−0.08 [−0.20, 0.04]) (Table 6).
11. Discussion
The amount of nutrients needed to prevent deficiencies, to
maintain body stores, and to reduce the risk of chronic
diseases represent the basis for establishing micronutrient
recommendations. Our meta-analysis was designed to quan-
tify the dose-response relationship between folate intake and
biomarkers of folate status. This information is useful to
decide what dose of folate or folic acid to recommend for
women planning a pregnancy, and subsequent lactation.
Previously, only Wald et al. [21] provided a quantitative
estimate of the dose-response relation between folic acid
intake, in doses of up to 1mg/day, and risk of NTD assessed.
They found that serum folate concentrations increase by 0.94
μg/L (95% CI = 0.77–1.10) for every 0.1mg/day increase in
folic acid intake in women aged 20–35 years. We applied a
base-e logarithmic transformation on the folate intake up
to 1mg/day and markers of folate status. The overall Beta
represents the diﬀerence in the ln-transformed predicted
value of serum/plasma folate status per one-unit diﬀerence
on the ln-transformed scale of folate intake. Therefore,
the relative change in intake to the power ̂β represents the
relative change in the biomarker concentration. For example,
the overall pooled Beta of 0.56 for women means that a 1.4-
fold increase of the mean intake from 250 to 350 μg/day
corresponds to a 1.21-fold increase in plasma folate, that
is, from an average of 16.0 to 19.3 nmol/L (=1.21 ∗ 16),
that is, 3.3 nmol/L per 100 μg/day, which is about 1.5 times
stronger than the estimated 2.13 nmol/L per 0.1mg/day as
estimated by Wald et al. [21]. Such a diﬀerence may be
explained by considering both the characteristics of the
studies included and the methodological approach used.
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Table 5: Forest plot of the eﬀects of total folate supply (i.e., supplement plus dietary folate), with the supplement in form of folic acid and
[6S]-5-methyltetrahydrofolate (5-MTHF) on red blood cell (RBC) folate in childbearing age, pregnant and lactating women.
Study or subgroup Beta SE Weight Beta
IV, Random. 95% CI
Beta
IV, Random, 95% CI
Folic acid
−1 −0.5 0 0.5 1
Brouwer et al., 1999 1 [26] 0.35741049 0.04126697 12.5% 0.36 [0.23, 0.44]
Ellison et al., 2004 [33] 0.53050104 0.09332632 11.1% 0.53 [0.35, 0.71]
Fohr et al., 2002 a [31] 0.53023607 0.04406458 12.5% 0.53 [0.44, 0.62]
Green et al., 2005 [32] 1.00981877 0.06717076 11.9% 1.01 [0.88, 1.14]
Houghton et al., 2006 f [36] 0.57853113 0.09878823 10.9% 0.58 [0.38, 0.77]
Lamers et al., 2006 c [18] 0.7384753 0.06637089 11.9% 0.74 [0.61, 0.87]
Lira et al., 1989 [34] 0.37051554 0.06476415 12.0% 0.37 [0.24, 0.50]
Mackey and Picciano, 1999 [20] 0.13206921 0.10234828 10.8% 0.13 [−0.07, 0.33]
Nogueira et al., 2003 [35] 0.94291343 0.24037313 6.3% 0.94 [0.47, 1.41]
Subtotal (95% CI) 100.0% 0.56 [0.40, 0.72]
Heterogeneity: Tau2 = 0.05; Chi2 = 102.70, df = 8 (P < 0.00001); I2 = 92%
Test for overall eﬀect: Z = 6.68 (P < 0.00001)
5-MTHF
Fohr et al., 2002 b [31] 1.65921221 0.05130933 35.0% 1.66 [1.56, 1.76]
Houghton et al, 2006 g [36] 0.74857769 0.17130372 31.0% 0.75 [0.41, 1.08]
Lamers et al., 2006 e [18] 1.06897313 0.0904731 34.0% 1.07 [0.89, 1.25]
Subtotal (95% CI) 100.0% 1.18 [0.65, 1.71]
Heterogeneity: Tau2 = 0.21; Chi2 = 50.98, df = 2 (P < 0.00001); I2 = 96%
Test for overall eﬀect: Z = 4.35 (P < 0.0001)
∗
The Authors kindly requested us to cite both the publication in AJCN [18] and Lamers’ Ph.D. thesis for the raw data [37].
RCB: red blood cell.
aSignificant diﬀerences between the baseline and the end of the treatment.
FA: folic acid.
MTHF: methyltetrahydrofolate.
Firstly, Wald and colleagues [21] included trials with and
without a placebo/control group in their analysis whilst we
used only data from randomized controlled trials. Moreover,
our review involved more updated references with respect
to the papers they evaluated, and only two studies were
included in our as well as their meta-analysis. Finally, Wald
and colleagues evaluated the eﬀect for given doses of folic
acid, not for total folate intakes (i.e., folic acid plus dietary
folate).
The main eﬀect found by pooling data from the selected
RCTs showed that folic acid plus dietary folate supply exerted
a significant eﬀect on all the markers of folate status, which
was particularly strong for RBC and plasma/serum folate.
Similarly, the meta-analysis by Mohamed [8] showed that
routine folate supplementation in pregnancy resulted in a
substantial reduction in the incidence of low serum and
RBC levels. However, the strength of the dose-response
relationships, we observed in pregnant women and in
lactating women was weaker than that found within women
in childbearing age. During these physiological periods
maintaining maternal biomarkers concentration at a given
level seems to be more diﬃcult. This may be due to the
anabolic needs of pregnancy and the loss via lactation.
Based on factorial approaches, folate requirements during
pregnancy are 5- to 10-fold higher than in the nonpregnant
condition, owing to the enlargement of the uterus, the
development of the placenta, the increasing red cell volume
of the mother, and the growth of the developing fetus
[17]. In breast feeding, milk folate secretion is strictly
regulated to keep folate supply at a level that prevents the
development of folate inadequacy in infants, but often at the
expense of maternal folate stores. Metz and colleagues [42]
demonstrated that folic acid was preferentially uptaken by
milk compared to serum. Moreover, the same authors found
that also in lactating women with severe folate deficiency,
oral administration of folic acid appeared to be transferred
to breast milk in preference even to the hemapoietic systems
[42].
It is worthwhile to note that all the RCTs included in
the meta-analysis were studies of supplementation. Supple-
mental amounts of folate are required to satisfy the increased
needs of women planning pregnancy, during pregnancy and
breastfeeding. Since natural food folates degrade during food
processing, and their bioavailability is low [7], folate intakes
from diet are found to be suboptimal from the perspective of
achieving an optimal folate status [6]. In contrast, folic acid,
that is, the synthetic form of folate, is highly bioavailable and
chemically stable, thus it is the most common form of folate
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Table 6: Forest plot of the eﬀects of total folate supply (i.e., supplement plus dietary folate), with the supplement provided in form of
folic acid and [6S]-5-methyltetrahydrofolate (5-MTHF) on plasma homocysteine (tHcy) folate in childbearing age, pregnant and lactating
women.
Study or subgroup Beta SE Weight
Beta
IV, random, 95% CI
Beta
IV, random, 95% CI
Folic acid
−25−0.5 0 0.50.25
Adank et al., 2003 [24] −0.12165995 0.05185699 11.9% −0.12 [−0.22, −0.02]
Brouwer et al., 1999 2 [25] −0.12939736 0.0321808 14.7% −0.13 [−0.19, −0.07]
Daly et al., 2002 [29] −0.07160639 0.05422432 11.5% −0.07 [−0.18, 0.03]
Ellison et al., 2004 [33] −0.41748287 0.08565077 7.7% −0.42 [−0.59, −0.25]
Fohr et al., 2002 a [31] −0.12081128 0.03080075 14.9% −0.12 [−0.18, −0.06]
Green et al., 2005 [32] −0.15712523 0.16696333 3.0% −0.16 [−0.48, 0.17]
Houghton et al., 2006 f [36] 0.02653085 0.04645807 12.7% 0.03 [−0.06, 0.12]
Lamers et al., 2004 n [30] −0.11673333 0.04042075 13.5% −0.12 [−0.20, −0.04]
Mackey and Picciano, 1999 [20] 0.05149742 0.06490784 10.1% 0.05 [−0.08, 0.18]
Subtotal (95% CI) 100.0% −0.10 [−0.17, −0.04]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.61, df = 8 (P = 0.0004); I2 = 72%
Test for overall eﬀect: Z = 3.26 (P = 0.001)
5-MTHF
Fohr et al., 2002 b [31] −0.01327471 0.03959555 37.5% −0.01 [−0.09, 0.06]
Houghton et al., 2006 g [36] −0.03682917 0.06823177 28.5% −0.04 [−0.17, 0.10]
Lamers et al., 2004 p [30] −0.19316684 0.0506911 34.0% −0.19 [−0.29, −0.09]
Subtotal (95% CI) 100.0% −0.08 [−0.20, 0.04]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.18, df =2 (P = 0.02); I2 = 76%
Test for overall eﬀect: Z = 1.34 (P = 0.18)
used in supplements and fortified foods. Interestingly, by
comparing the strength of associations between total folate
intake and folate status, we observed that the relationship
tended to be stronger for 5-MTHF than for folic acid. Some
authors suggested that 5-MTHF was as eﬀective as or more
eﬀective than folic acid in preserving folate status [17, 18, 36]
given that 5-MTHF is the predominant folate transport and
storage form within the body. Use of the naturally occurring
folate form 5-MTHF as a possible substitute for folic acid is
under consideration because it is unlikely to mask vitamin B-
12 deficiency, and does not produce unmetabolized folic acid
in the circulation in contrast to folic acid [43].
The main strength of this meta-analysis is the selection of
data from randomized controlled trials. Ideally, RCTs should
provide reliable data about the eﬀect of an intervention.
This means that changes in folate indicators are definitely
due to folic acid/folate intervention. However, it has to be
taken into account that after the Medical Research Council
Vitamin Study [16] studies designed to assess the eﬀect of
folic acid intake on measures of folate status in the pericon-
ceptional period cannot be studied in controlled trials due
to ethical reasons. Folic acid supplementation is recognized
indispensable around conception in protecting against NTDs
because the neural tube closes between 23rd and 27th day of
pregnancy. Thereby, the application of our inclusion criteria
lets us to exclude several studies on this topic because they
were not RCTs. Moreover, we found that there is an overall
lack of research regarding the role of folate in pregnancy
outcomes diﬀerent fromNTDs. Further research is needed to
investigate the role of folate supply in the latter two trimesters
of pregnancy. An adequate folate intake seems in fact to
play an important role in the implantation and development
of the placenta, and in improving endothelial function,
to suggest that adequate amount of folate might also be
beneficial along the entire gestation [7]. Similarly, functional
or health outcomes of various folic acid/folate intakes have
been rarely explored in lactating women. On the whole, in
fact, trials included in this review mostly recruited women
of childbearing age, while trials on women during pregnancy
and lactation are scarce, suggesting that further research is
needed to explore this question. Most of the trials included
small size samples. Moreover, our assessment of internal
validity showed that most of the studies had a moderate
to high risk of bias as assessed by our criteria. We found a
great heterogeneity among trials probably due to diﬀerences
in methodological factors and physiological characteristics
of women studied. However, the analysis of the potential
influence of folic acid dose, duration of supplementation, or
population on the association revealed that these factors did
not significantly explain the between-study heterogeneity.
12. Conclusion
Statistically significant relationships between total folate
intake and serum/plasma folate, red blood cell folate and
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tHcy were shown. In particular, a doubling of the total folate
intake significantly increased the folate concentration level in
serum/plasma and RBC by 47% and 23%, respectively, and
lowered the levels of plasma tHcy by 7%. This dose-response
approach here applied may in future be applied for deriving
the intake dose necessary to achieve the optimal level of a
folate biomarker for women of childbearing age, as well as
for pregnant and lactating women.
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